The epitope recognized by the antibody resides within amino acids 122-168 of human Bcl-10 molecule.
Formulation:
This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. Final antibody concentration is 0.5 mg/ml.
Preparation:
The antibody was purified by protein G affinity chromatography
Concentration:
0.5 mg/ml
Storage & Handling:
Upon receipt, store at 4°C.
Application:
WB1 - Quality tested ELISA, IHC(P)1,2 - These applications have been reported in the literature.
Recommended Usage:
Each lot of this antibody is quality control tested by Western blotting. Western blotting, suggested working dilution(s): Use 5 µg antibody per 5 ml antibody dilution buffer for each mini-gel. It is recommended that the reagent be titrated for optimal performance for each application.
Application References:
1. Ye, H. et al. 2000. Am. J. Pathol. 157:1147. 2. Ye, H. et al. 2003. Blood. 102:1012.
Western blot analysis of extracts from Jurkat cells, using anti-Bcl10, clone 151.
Description:
BCL10 promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK.It may be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex.A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma), translocation t(1;14)(p22;q32). Defects in BCL10 are involved in various types of cancer.
Other Names:
B-cell CLL/lymphoma 10, CIPER, CLAP
Structure:
Contains 1 CARD domain. Predicted MW, 26 kD.
Distribution:
Cytoplasm › perinuclear region
Function:
Bcl10 promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK.
Regulation:
Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2.
Interaction:
MALT1, TRAF2, Caspase-9, BIRC2/c-IAP2
Antigen References:
1. Willis, T.G. et al. 1999. Cell 96:35. 2. Zhang, Q. et al. 1999. Nat. Genet. 22:63. 3. Yui, D. et al. 2001. Oncogene 20:4317.
